Boteng: net profit in the first half of the year increased by 60% - 70% year on year
According to the announcement of Boteng, the net profit in the first half of 2021 is expected to be 210 million yuan – 223 million yuan, with a year-on-year growth of 60% - 70%. Under the background of steady growth of global pharmaceutical R & D pipeline and increasing trend of pharmaceutical R & D outsourcing, the company has continuously consolidated the achievements of cdmo strategic transformation, continuously expanded and enriched product pipeline, continuously improved technical capability and product delivery capability, and continuously improved the company's ability to obtain orders. In the first half of 2021, the company expects to achieve a 30% - 40% increase in operating revenue compared with the same period last year.
This text is a result of machine translation.
Related companies：
In-depth
Briefing May 19, 2022 11:34 AM
· Financials
The index recovered, and the gem index and Shanghai index once turned red
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
May 11, 2023 05:07 PM
Jan 06, 2023 08:30 AM
Briefing Mar 13, 2022 04:38 PM
Dongfang Yuhong: adjust the prices of some main products of the company, among which the asphalt coiled material is increased by 15% - 20%.
Donghua Technology: pre winning the EPC project of ammonium dihydrogen phosphate project for battery
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
“Go Global or Go Down”.A new wave of Chinese culinary expansion overseas has emerged, with an increasing number of Chinese restaurant brands stepping onto the international stage. While Southeast Asia and Europe and America remain primary territories for Chinese cuisine abroad, Latin America, the farthest from China, also eagerly anticipates the arrival of Chinese restaurant brands, longing to experience the unique charm of Chinese cuisine.
Updated 46 mins ago
Consumer Discretionary
PEELSPHERE Secures CNY Tens of Mn in Pre-A Round Financing
EqualOcean has learned that PEELSPHERE(朴飞生物) has successfully completed a pre-A round financing of tens of millions of RMB, with investors including Guohong Jiaxin Capital and Ray Capital, while existing shareholder Gopher Ventures continues to follow-on invest. This funding will primarily be used for production line upgrades, new product development, and market expansion.
Yesterday 07:10 PM
Market shock consolidation, public offering and private placement increased positions simultaneously
Briefing Dec 20, 2021 08:58 AM
Bufeng international calls out the list of Hong Kong stocks under Shenzhen Hong Kong stock connect
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Updated 46 mins ago
Insight
In-depth